Roivant parlays a $450M chunk of equity in biotech buyout, grabbing a computational group to drive discovery work
New Roivant CEO Matt Gline has crafted an all-equity upfront deal to buy out a Boston-based biotech that has been toiling for several years now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
